These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 12847582)
1. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Toren P; Ratner S; Laor N; Weizman A Drug Saf; 2004; 27(14):1135-56. PubMed ID: 15554747 [TBL] [Abstract][Full Text] [Related]
2. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder. Gunasekara NS; Spencer CM; Keating GM CNS Drugs; 2002; 16(9):645-52. PubMed ID: 12153335 [TBL] [Abstract][Full Text] [Related]
3. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. Krzystanek M; Krupka-Matuszczyk I Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416 [TBL] [Abstract][Full Text] [Related]
5. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Gunasekara NS; Spencer CM; Keating GM Drugs; 2002; 62(8):1217-51. PubMed ID: 12010089 [TBL] [Abstract][Full Text] [Related]
6. Quetiapine versus other atypical antipsychotics for schizophrenia. Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315 [TBL] [Abstract][Full Text] [Related]